Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1017-1025 |
| Number of pages | 9 |
| Journal | Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends |
| Volume | 19 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Fingerprint
Keywords
- Animals
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Drug Therapy, Combination
- Female
- Humans
- Hypoglycemia
- Hypoglycemic Agents
- Insulin Resistance
- Male
- Pyrazines
- Thiazolidinediones
- Triazoles
Cite this
}
Fixed-dose combination therapy for type 2 diabetes : sitagliptin plus pioglitazone. / Bailey, Clifford J.; Green, Brian D.; Flatt, Peter R.
In: Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends , Vol. 19, No. 8, 08.2010, p. 1017-1025.Research output: Contribution to journal › Article
TY - JOUR
T1 - Fixed-dose combination therapy for type 2 diabetes
T2 - sitagliptin plus pioglitazone
AU - Bailey, Clifford J.
AU - Green, Brian D.
AU - Flatt, Peter R.
PY - 2010/8
Y1 - 2010/8
N2 - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
AB - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
KW - Animals
KW - Clinical Trials as Topic
KW - Diabetes Mellitus, Type 2
KW - Dipeptidyl-Peptidase IV Inhibitors
KW - Drug Therapy, Combination
KW - Female
KW - Humans
KW - Hypoglycemia
KW - Hypoglycemic Agents
KW - Insulin Resistance
KW - Male
KW - Pyrazines
KW - Thiazolidinediones
KW - Triazoles
UR - http://www.scopus.com/inward/record.url?scp=77954713342&partnerID=8YFLogxK
U2 - 10.1517/13543784.2010.505235
DO - 10.1517/13543784.2010.505235
M3 - Article
C2 - 20629618
VL - 19
SP - 1017
EP - 1025
JO - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends
JF - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends
SN - 1354-3784
IS - 8
ER -